XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. COVID-19 Clinical Trials.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

XTalks

OCTOBER 24, 2024

AX-158 offers a new class of therapy, by targeting immune responses without causing immunosuppression, making it a potentially safer option for long-term treatment, with results expected by the end of 2024.

Research 105

Research Dermatology Clinical Trials Clinical Trials 105

Worldwide Clinical Trials

JUNE 21, 2024

The 2024 ASCO Annual Meeting from the American Society of Clinical Oncology is a fantastic platform for clinical researchers to discuss the latest advancements and challenges in oncology research. Response Rates : To date, approximately 30% of patients are achieving objective responses, indicating considerable room for improvement.

Antibody 162

Antibody Clinical Trials Clinical Trials In-Vitro 162

Pharmaceutical Technology

JULY 18, 2022

In clinical trials, the adjuvanted formulation induced the necessary immune response using a reduced amount of antigen versus a formulation without adjuvant, indicating that more doses could be available during a pandemic.

Vaccination 162

Vaccination Vaccine Immune Response Clinical Trials 162

Pharmaceutical Technology

MAY 10, 2023

XinThera’s therapy targeting MK2 is expected to enter clinical trials later in 2023. The acquisition will give Gilead Sciences access to XinThera’s portfolio of two small molecule inhibitor programmes, one of which targets PARP1 to treat cancer and the other of which targets MK2 for inflammatory diseases.

Immune Response 130

Immune Response DNA Clinical Trials Clinical Trials 130

Camargo

DECEMBER 13, 2021

The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. The regulations regarding BLAs for therapeutic biological products are included in 21 CFR parts 600 , 601 , and 610.

Development 161

Development Production Immune Response Licensing 161

The Pharma Data

AUGUST 16, 2021

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV. “In Induction of innate immunity was investigated via specific cytokine markers.

Immune Response 52

Immune Response Vaccination Vaccine Antibody 52

Pharmaceutical Technology

JANUARY 19, 2023

In the Phase II trials, adult participants received a single Nuvaxovid booster dose six months after their initial two-dose vaccine doses. The findings showed that the Nuvaxovid booster dose increased immune responses compared to higher levels associated with the protection in Phase III clinical trials.

Vaccination 147

Vaccination Vaccine Immune Response Protein 147

Pfizer

FEBRUARY 16, 2023

These study participants, representing approximately half of the total recruited participants in the trial, are being discontinued following violations of Good Clinical Practice (GCP) at certain clinical trial sites run by a third-party clinical trial site operator.

Clinical Trials 76

Clinical Trials Clinical Trials Vaccination Vaccine 76

XTalks

DECEMBER 30, 2024

SLE is an autoimmune disease where the immune system attacks healthy tissues, causing inflammation, pain and potential organ damage. Cenerimod modulates the immune response, reducing inflammation and preventing the production of harmful autoantibodies.

Immune Response 52

Immune Response Gene Expression Drugs Trials 52

The Pharma Data

DECEMBER 20, 2020

UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. . In October, Scancell signed a manufacturing deal for SN14 with Cobra Biologics, a Cognate BioServices subsidiary, ahead of a planned phase 1 trial in 2021.

Clinical Trials 52

Clinical Trials Clinical Trials Pharma Companies Vaccination 52

Worldwide Clinical Trials

JUNE 15, 2022

There have been a few cases lately where patients receiving gene therapy had a severe adverse effect because of their immune response to the mechanism of the AAV viral vector, based on their own genomic markers. 5 Things You Need to Know from Our Recent Gene Therapy Webinar appeared first on Worldwide Clinical Trials.

Gene Therapy 130

Gene Therapy Gene Clinical Trials Clinical Trials 130

The Pharma Data

DECEMBER 23, 2020

In the context of a substantial amount of COVID-19-related research and the launch of numerous clinical trials, the French government created this steering committee to prioritize and accelerate high potential clinical trials. This Phase IIa trial follows a preliminary study conducted by Prof. Marc Derive.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Research 52

The Pharma Data

SEPTEMBER 25, 2020

Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate. Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate. Immune responses were similar across the age groups studied, including older adults.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

The Pharma Data

JUNE 26, 2021

Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine. Th e first clinical trial of a seasonal mRNA flu vaccine candidate is an exciting milestone in our quest for the next generation of inf lu enza vaccines. JUNE 22 , 2021.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

pharmaphorum

FEBRUARY 9, 2022

The oncology segment has been recognised as one of the most productive areas for pharmaceutical companies to focus their R&D investment. While therapeutic cancer vaccines are able to help the body identify particular proteins expressed by cancer cells and then to instigate an immune response. over the last five years.

Vaccination 134

Vaccination Vaccine Clinical Trials Clinical Trials 134

Pharmaceutical Technology

FEBRUARY 26, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It constitutes tumor infiltrating lymphocytes (TILs) isolated from the patient’s tumor further expanded and then infused back to the patient enabling patient robust immune response.

Immune Response 100

Immune Response Production Drugs Clinical Trials 100

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. The Companies expect interim results from this trial in the third quarter of 2021. About the Phase 1/2 clinical trial.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

XTalks

MARCH 13, 2023

The US Food and Drug Administration’s (FDA) Office of Tissues and Advanced Therapies (OTAT) held a recent town hall where three experts from the regulator provided guidance on how to design and conduct gene therapy clinical trials for rare diseases. All except for Adstiladrin were cleared for rare disease indications.

Gene Therapy 52

Gene Therapy Gene Clinical Trials Clinical Trials 52

pharmaphorum

JULY 18, 2022

MBA, managing director at CanSino Biologics Europe, tells us about Convidecia, a single dose SARS-CoV-2 vaccine offered as an injectable and inhalant that allows ease of storage, an alternative option for individuals with needle phobias, and robust elongated CD4 and CD8 cellular response. Morgon, PharmD, LL.M, The inhalant version.

Vaccination 138

Vaccination Vaccine Development Immune Response 138

The Pharma Data

APRIL 15, 2022

NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive results from a Phase 2/3 clinical trial evaluating the safety, tolerability and immunogenicity of a 10-µg booster (third) dose of the Pfizer-BioNTech COVID-19 vaccine in healthy children 5 through 11 years of age. About the Phase 1/2/3 Trial in Children.

Immune Response 52

Immune Response Vaccination Vaccine Clinical Trials 52

XTalks

NOVEMBER 23, 2020

The global trials are assessing the safety and efficacy of the vaccine in individuals aged 18 years or over from diverse racial and geographic groups who are healthy or have stable underlying medical conditions. Oxford-AstraZeneca COVID-19 Vaccine Induces Immune Responses in Early Clinical Trials.

Vaccination 97

Vaccination Vaccine Clinical Trials Clinical Trials 97

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. The phase 1 clinical trial was a randomized, double-blind and placebo-controlled study in 150 adult and elderly participants.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

XTalks

SEPTEMBER 15, 2020

A vaccine developed by Swedish company Diamyd Medical has demonstrated significant treatment efficacy in a predefined genetic subgroup of individuals with type 1 diabetes in a Phase IIb clinical trial. Diamyd Medical is a clinical-stage biopharmaceutical company that develops therapies for type 1 diabetes. cells of the pancreas.

Vaccination 103

Vaccination Vaccine Insulin Trials 103

pharmaphorum

FEBRUARY 8, 2021

This is the second vaccine approved by China’s National Medical Products Administration (NMPA). Brazilian clinical trial results published last month showed the vaccine, dubbed Coronavac, is just over 50% effective. China’s national regulator has approved Sinovac Biotech’s COVID-19 vaccine for use by the general public.

Vaccination 90

Vaccination Vaccine Immune Response Regulation 90

pharmaphorum

SEPTEMBER 24, 2020

The UK is already leading research into potential therapies and vaccines for the virus – unfortunately as one of the worst-hit countries there have been enough patients available to run large-scale national clinical trials.

Vaccination 98

Vaccination Vaccine Trials Immune Response 98

Pfizer

JULY 26, 2022

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to evaluate the safety, tolerability, and immune response of an enhanced COVID-19 mRNA-based vaccine candidate at a 30 µg dose level. INTERCHANGEABILITY.

Vaccination 111

Vaccination Vaccine Protein Immune Response 111

XTalks

SEPTEMBER 5, 2023

Boceta-Muñoz: One major challenge that exists is the production and distribution of vaccines for resource-constrained settings, which slows down the process of achieving global coverage. Investigation of the possibility of VAED is crucial during clinical trials for decision-making on vaccine licensing by regulatory agencies.

Vaccination 96

Vaccination Vaccine Development Clinical Trials 96

pharmaphorum

NOVEMBER 29, 2022

Number of on-going clinical trials: 14. T cells are known to mediate anti-tumor immune responses. For that reason, they have become the key target of immune checkpoint therapies, like PD-(L)1 agents. Locations: 3 (US HQ, Korea office, Korea R&D center). Number of employees: 90+ (as of Oct. Creation: Jan.

Clinical Trials 105

Clinical Trials Clinical Trials Trials Engineer 105

XTalks

DECEMBER 14, 2021

Moderna revealed the first interim results from a small, Phase I study of its mRNA-based influenza vaccine, which showed that the vaccine had no significant safety concerns and elicited immune responses against four strains of the influenza virus. There were no significant safety findings reported through day 29. Mixed Results.

Vaccination 98

Vaccination Vaccine Immune Response Antibody 98

The Pharma Data

DECEMBER 8, 2020

a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce an oversubscribed $8 million financing. VANCOUVER, British Columbia, Dec. 09, 2020 (GLOBE NEWSWIRE) — Qu Biologics Inc. ,

Immune Response 52

Immune Response Clinical Trials Clinical Trials Production 52

Delveinsight

AUGUST 26, 2021

Any products from the collaboration will be developed and commercialized by Roche. The company then utilizes the de-identified records to improve the design of clinical trials and quality of life measurements. Rare disease data-focused AllStripes raises USD 50 Million to enhance medical record mining.

Vaccination 98

Vaccination Vaccine Gene Therapy RNA 98

pharmaphorum

NOVEMBER 30, 2020

In serious cases, higher levels of pre-existing NAbs can even cause a dangerous immune reaction when such therapies are administered. This is particularly pertinent in rare diseases, as a number of gene therapy products use viral delivery methods to deliver the transgene to target organs.

Gene Therapy 105

Gene Therapy Gene Antibody Clinical Trials 105

The Pharma Data

NOVEMBER 14, 2020

The interim analysis showed that a single dose of the COVID-19 vaccine candidate induced a robust immune response and was generally well-tolerated. PHASE 3 ENSEMBLE 2 STUDY. Janssen will aim to enroll participants in Belgium, Colombia, France, Germany, the Philippines, South Africa, Spain, the United Kingdom and the United States.

Clinical Trials 40

Clinical Trials Clinical Trials Vaccination Vaccine 40

pharmaphorum

MARCH 4, 2021

Sunak pledged £28 million towards the UK’s capacity for vaccine testing, support for clinical trials and to improve the ability to acquire samples of new COVID-19 variants. The guidance comes from the ACCESS Consortium of regulators from the UK, Australia, Canada, Singapore and Switzerland.

Vaccination 105

Vaccination Vaccine Development Life Science 105

Cloudbyz

MARCH 5, 2024

The difference between biologics vs small molecules in pharma drug development In pharmaceutical drug development, biologics and small molecules represent two distinct categories of medicinal products, each with their own unique characteristics, development processes, and mechanisms of action.

Development 97

Development Drugs Immune Response Manufacturing 97

pharmaphorum

APRIL 14, 2022

Epcoritamab is a bispecific antibody which targets CD3 on white blood cells and CD20 on tumour cells, and is designed to encourage an immune response against the cancer. billion product at peak. Analysts at Jefferies have previously said they think epcoritamab could become a $1.5

Licensing 64

Licensing Licensing Immune Response Antibody 64